|
|
| (294 intermediate revisions by 7 users not shown) |
| Line 1: |
Line 1: |
| {{MITOEAGLE}} | | {{MITOEAGLE}} |
| | [[File:MITOEAGLE-representation.jpg|right|400px|link=http://www.mitoeagle.org/index.php/MitoEAGLE|COST Action MitoEAGLE]] |
| | <div style="margin:0.5em; background:#cedff2; font-family:inherit; font-size:120%; font-weight:bold; border:1px solid #a3b0bf; color:#FF0000; padding:0.2em 0.4em;"> |
| | <div id="mp-itn" style="padding:0.1em 0.6em;"> |
| | <div id="mp-itn" style="padding:0.1em 0.6em;">[[File:MitoPathways Suppl Poster doi10.26124bec2020-0002.s1.jpg|center|450px|link=https://wiki.oroboros.at/images/2/29/MitoPathways_Suppl_Poster_doi10.26124bec2020-0002.s1.jpg|MitoPathways Suppl Poster]]</div> |
| | ::::::::::* '''Mitochondrial Physiology and Blue Book MitoPathways Poster'''<br> |
| | :::::::::::- » [[BEC 2020.1 doi10.26124bec2020-0001.v1 |MitoEAGLE Task Group BEC 2020.1]] |
| | :::::::::::- » [[Gnaiger 2020 BEC MitoPathways |Gnaiger 2020 MitoPathways BEC 2020.2]] |
| | </div> |
| | </div> |
|
| |
|
| __TOC__ | | __TOC__ |
| == COST Action MITOEAGLE approved ==
| |
|
| |
|
| :::'''Top news 2016-02-12''' | | == MitoEAGLE today == |
| | === MitoEAGLE dissemination === |
| | :{| |
| | | width="100" align="left" | [[File:Shipment cover letter.jpg|Cover letter for the MitoEAGLE shipment|900px|link=https://wiki.oroboros.at/images/f/fe/Cover_letter_Shipment.pdf]] |
| | | |
| | :::::::::<small> Shipments ready to go from [http://www.steigerdruck.com/ Steiger Druck, Axams] </small> |
| | :::::[[File:Blue book shipment 1.jpg|300px|right]]<br> |
| | :::::[[File:Blue book shipment 2.jpg|300px|right]]<br> |
| | :::::[[File:Blue book shipment 3.jpg|300px|right]] |
| | |} |
| | *[[Media:MitoEAGLE Success Story FFG.pdf |MitoEAGLE Success Story]] |
| | *[[Media:MitoEAGLE PR FFG.pdf| MitoEAGLE PR FFG]] |
| | === Bioenerg Commun - Mitochondrial physiology received === |
| | [[File:Cellomet Poster.jpg|180px|right|Poster at Cellomet]] [[File:Poster Lab RS 1.jpg|100px|right|Poster at Lab in Serbia]] [[File:Poster Lab RS 2.jpg|100px|right|Nina Krako with the Poster]] |
| | ::::* [[Boros Mihaly]]: The package has arrived, thank you so much for the wonderful Easter gift! There is an incredible amount of work in it, and I/we are so glad that we were part of it, if only a little bit. I have started to distribute the booklets among the students, I do hope that there will be an opportunity for them to meet you in person in postcovid times. With my best personal regards. |
|
| |
|
| :::: <big>'''''We are happy to inform you that proposal OC-2015-2-19984 Mitochondrial mapping: Evolution - Age - Gender - Lifestyle - Environment was approved by the COST Committee of Senior Officials.'''''</big> | | ::::* [[Pirkmajer Sergej]]: Thank you very much for the materials that you had sent. It was a nice surprise to receive the package today! |
| :::- ''More details'' '''» [[COST Action MITOEAGLE]]'''
| |
|
| |
|
| :::'''Evaluation highlights''' | | ::::* [[Andric Silvana]]: My appreciation to you, Prof. Gnaiger, Marija, Feiyuan and all others working on the material is more than I express. It will be of great help to our students. |
| :::: The proposal addresses the considerable lack of uniformity and consensus on standard operating procedures in the design and implementation of research protocols involving mitochondrial physiology. This is a very real problem that can only be solved through networks on a scale such as this Action, that will work to harmonise experimental protocols across research groups. | |
| :::- ''More details'' '''» [[MITOEAGLE evaluation highlights]]'''
| |
|
| |
|
| | ::::* [[Oliveira Paulo J]]: Just received today the brochures and materials from Oroboros, which I have distributed already. The poster is amazing and I kept one for my lab and one for me. Thanks again for sending those materials. |
|
| |
|
| == S&T Excellence ==
| | ::::* [[Sumbalova Zuzana]]: Thank you very much for the teaching material. We appreciate your hard work and will use the material for better understanding, presentation and teaching in the field of mitochondrial physiology. |
|
| |
|
| === Challenge ===
| | ::::* [[Hickey Anthony J]]: We must thank you for the documents you sent through. These came just as I had to run a tutorial for my new students. |
| '''Main aim'''
| |
| :::: Every study of mitochondrial function and disease in human tissues and cells is faced with '''E'''volution, '''A'''ge, '''G'''ender, '''L'''ifestyle and '''E'''nvironment ('''EAGLE''') as essential background conditions characterizing the individual patient, subject, study group, species, tissue or – to some extent - cell line. This range of factors is too wide to be accommodated in any single project on mitochondrial respiration. Only a large and '''well coordinated network''' can manage to generate the necessary number of consistent data to address the complexity of EAGLE. The MITOEAGLE knowledge management network will be a strategic innovation to develop harmonization protocols towards generating a rigorously monitored data repository on mitochondrial respiratory function. A '''MITOEAGLE data management system''' is necessary to interrelate results of a large number of studies, to interpret pathological phenotypes, and to set results into the multidimensional context of EAGLE. Clearly, MITOEAGLE must be operated by mitochondrial specialists on a global scale. MITOEAGLE will be a gateway and milestone to better diagnose mitochondrial respiratory defects which are linked to various age-related health risks, including cardiovascular and degenerative diseases, such as type 2 diabetes, neurodegenerative diseases (Alzheimer’s, Parkinson’s, Huntington’s), and several types of cancer (Murdoch 2013 JAMA). | |
|
| |
|
| '''Relevance and timeliness'''
| | ::::* [[Aasander Frostner Eleonor]]: thank you for sending us the Mitochondrial Physiology/MitoPathways teaching materials that we requested after the circular! It arrived safely to the lab. |
| :::: Diseases that are strongly related to a sedentary life style are spreading world-wide at an epidemic scale. Mitochondrial dysfunction is increasingly associated with the progression of such pathologies: cause or consequence? There is currently no regimented, quantitative system, or database organised to routinely test, compare and monitor mitochondrial capacities within individuals, populations, or among populations. This reflects the need for scientific innovation and represents a shortcoming in the health system of our modern, rapidly ageing society. Traditional lifestyles of ‘remote’ human populations are dwindling such that these highly significant windows into our evolutionary past are about to becoming closed, forever. While studies of mitochondrial DNA (mtDNA) have become increasingly established in the search for the evolutionary history and diversification of the human species, mitochondrial function remains comparatively unexplored, but may turn out to provide key information for preventing diseases which become prevalent upon transition to a Westernized lifestyle. The presently observed acceleration of research on cell and mitochondrial respiration represents a challenge to transform scientific information into knowledge and translate complex results on mitochondrial (dys)function into a patient-related mitochondrial score. Diagnostic standards, however, are lacking. A concerted action of the scientific community is required to implement quality control systems and optimally harmonize protocols across research groups. The primary challenge is to ‘increase value and reduce waste in research design, conduct, and analysis’, to separate the signal from the noise (Ioannidis 2005; The Lanzet 2014): ‘The signal is the truth. The noise is what distracts us from the truth’ ([[Silver 2012 Penguin Press |Silver N: The signal and the noise. The art and science of prediction. Penguin Press 2012]]). | |
|
| |
|
| === Objectives ===
| | ::::* [[Cervinkova Zuzana]]: I would like to thank you very much for a package with publications and teaching material which I received. I distributed the Blue Book and publications among my colleagues and others. It is pity that the pandemic caused complications in the completion of our project and hinders our meetings. Hopefully this will end soon. |
|
| |
|
| '''Research coordination objectives'''
| | ::::* The Mitopathway comprehensive poster kindly sent by Oroboros and BEC is now displayed [http://www.cellomet.com/ @CELLOMET_news] laboratory just behind the O2k and the O2k-Fluo systems. See Twitter post [https://twitter.com/CELLOMET_news/status/1380158353939259395/photo/1 here] - [[FR Bordeaux Rossignol R]] |
| :::: MITOEAGLE aims at providing the first standardized measures to link mitochondrial and physiome performance (heart rate, BMI, blood pressure, blood chemistry, ''V''<sub>O2max</sub>) to understand the myriad of factors that play a role in mitochondrial physiology. The ambitious objective to optimally harmonize protocols across research groups cannot be achieved through projects with limited numbers of partners. Therefore, the COST framework represents an ideal instrument which allows bringing together many groups and experts in the diverse field of mitochondrial physiology. The aim of this Action is to form a unique well-coordinated network of senior researchers and young investigators, to include well established stakeholders, and to establish a spirit of mentorship and collaboration in contrast to fierce competition which characterized early decades of bioenergetics. The COST format is perfectly suited for achieving these objectives. | |
|
| |
| :::: These objectives will be realised by using the following instruments: | |
| ::::# Network meetings, workshops.
| |
| ::::# Working Groups (WG).
| |
| ::::# Short Term Scientific Missions (STSM).
| |
| ::::# Discussion forum and websites in order to report effectively the COST Action progress.
| |
|
| |
|
| :::: Members of the MITOEAGLE consortium may be active in more than one WG, thus allowing substantial crosstalk between the groups and interactions between different disciplines. | | ::::* [[Rich Peter R]]: thanks for the package - very useful and beautifully produced material. I will put a poster up in the lab. when I get back there. |
|
| |
|
| :::: These instruments are directed towards the following aims of the MITOEAGLE COST Action: | | ::::* [[Krako Jakovljevic Nina]]: Thank you very much for the dissemination material you sent us. It is very useful and very well prepared. Here some photos of the MitoPathways posters in our lab in Serbia. - [[RS Belgrade Lalic NM]] |
| ::::# Intensify the dissemination of updated knowledge and know-how among the partners;
| |
| ::::# Build and improve collaborative relationships among the participating groups of the Action and interested end-users;
| |
| ::::# Foster coordinated research activities of scientific proposals in the European Research Area;
| |
| ::::# Increase the number of active participants in the course of the COST Action;
| |
| ::::# Initiate applications for funding to support international collaborative research projects;
| |
| ::::# Present and publish results of collaborative research projects within the COST Action, particularly related to STSM supported by the Action.
| |
|
| |
|
| '''Capacity-building objectives'''
| | == MitoEAGLE time schedule - how it flies == |
|
| |
|
| ::: '''MITOEAGLE recommendations''' | | :::: This is the '''roadmap''' of the project; yet the expression "'''''how it flies'''''" belongs to EAGLE. |
| :::: - increase the value and reduce the noise: Enthusiastic and authentic opinion leaders can bring about a change to increase the value and reduce the noise in mitochondrial research specifically, biomedicine at large, and in our society in general. Millions of Euros are wasted on research that is lacking coherent standards. Prespecified and time-stamped protocols are needed in practice, and researchers need to be introduced into adhering to publicly deposited protocols in practice (Begley, Ioannidis 2015). MITOEAGLE recommendations will provide practical guidelines for students, scientists and stakeholders.
| |
|
| |
|
| ::: '''A monitored database – centres of excellence'''
| | ::'''[[COST_MitoEAGLE_reimbursement_information|COST MitoEAGLE reimbursement information]]''' |
| :::: The MITOEAGLE database will provide an invaluable tool for mitochondrial studies in the transition from exploratory preclinical research to clinical and pharmacological applications. Centres of excellence will emanate from the project’s working groups providing training programmes and diagnostic services.
| |
|
| |
|
| ::: '''Training'''
| | === Chronological list of MitoEAGLE Events === |
| :::: Enhance the rigorous training activities particularly for PhD students and young researchers (STSM, Schools, Workshops, Conferences) in order to establish the practical guidelines introduced by MITOEAGLE and to enhance research results in the long term.
| |
|
| |
|
| === Progress beyond the state-of-the-art and innovation potential === | | {{#ask:[[Category:Publications]] [[Additional label::MitoEAGLE]] |
| | |?Was published in year=Date |
| | |?Has title=Location - Country |
| | |format=broadtable |
| | |limit=5000 |
| | |offset=0 |
| | |sort=Was published in year |
| | |order=descending |
| | }} |
|
| |
|
| '''Description of the state-of-the-art'''
| | {{MITOEAGLE Grant Periods}} |
| :::: The capacity and efficiency of energy transformation through the pathways of mitochondrial core energy metabolism represent key features of the mitochondrial phenotype. Performance parameters of oxidative phosphorylation (OXPHOS) are not available in a consistent format for cataloguing as defined ‘core variables’ and, therefore, are not represented in presently available databases. In contrast, many research groups are working on extensive documentation of genetic, epigenetic, transcriptomic, proteomic, lipidomic and metabolomic datasets in various fields of basic and clinical research, including mitochondrial medicine. Relevant techniques include next-generation sequencing to determine the genome (nDNA and mtDNA), methylome, and the transcriptome (RNA), and mass spectrometry for analysis of the proteome, lipidome, and metabolome. Such data are becoming available through various portals, some of which provide Open Access to allow researchers to use the data for their specific needs and data mining. The quality of any database is not better than the quality of the primary constituent datasets. Rigorous standards have to be applied to forge information into knowledge. Comparability of data generated by different labs on OXPHOS performance is restricted due to different laboratory protocols applied. Harmonization is clearly required along these lines, including the establishment of mitochondrial reference samples for inter-laboratory proficiency tests, and guidelines for data analysis and reporting (http://www.equator-network.org/).
| |
|
| |
|
| '''Progress beyond the state-of-the-art'''
| |
| :::: The COST Action MITOEAGLE aims at developing a quality management system (QMS), defining common standards for measurements in the field of mitochondrial function. The following protocols shall be defined in the course of the Action, so that the participants can finally agree on a set of well documented standard operating procedure (SOP) protocols:
| |
|
| |
|
| ::::# Solution protocols: media, substrates, uncouplers, inhibitors used in SUIT protocols, permeabilization agents, etc. | | == MitoEAGLE topics == |
| ::::# Instrumental performance protocols | | :::* New Vademecum: [http://wiki.oroboros.at/images/c/cd/COSTVademecum_neu.pdf open here] |
| ::::# Mitochondrial preparation protocols, including biopsy sampling, tissue storage, cell preparation protocols, etc.
| | :::: Summary of the changes - [[File talk:COSTVademecum neu.pdf]] |
| ::::# Respirometric OXPHOS data acquisition and analysis protocols.
| |
|
| |
|
| [[File:MITOEAGLE concept.jpg|right|400px|MITOEAGLE concept]]
| |
| :::: The Action will elaborate definitions of fundamental terms as required by the data management system, including a review on normalization of the data (tissue mass, cell protein, mt-markers such as mt-volume, mt-protein, mt-marker enzymes, flux ratios).
| |
|
| |
|
| :::: A User Requirement Document will define the strategy and tools required for a MITOEAGLE database, which will be elaborated for initiation of a data repository designed to ultimately describe the linkage between the mt-phenotype and a variety of factors (Mitochondrial Fitness Mapping, Fig. 1). E in EAGLE includes genetic variables. Depending on sample selection (human studies and animal models) as well as tissues and cell types, specific SOPs are summarized for various mt-preparations (Fig. 1). Adherence to common standards is likely to increase the proportion of true findings (Ioannidis 2005; Fortier et al 2010). A data bank with harmonized datasets will advance significantly the field of human and comparative bioenergetics research and provide the level of knowledge required for helping health systems to evolve. | | :::* [https://www.frontiersin.org/research-topics/10336/mitochondrial-proteomics-understanding-mitochondria-function-and-dysfunction-through-the-characteriz?fbclid=IwAR3xM__MqwDBZ7wjab6UI-QJ5mNtkcUgv9O_AvMlq69zjpYuYArICS_prKU#overview Mitochondrial Proteomics: Understanding Mitochondria Function and Dysfunction Through the Characterization of Their Proteome] |
|
| |
|
| '''Innovation in tackling the challenge'''
| |
| :::: Scientists may refute the challenge of comparing, optimizing and even pre-registering their protocols, when employment and assessment procedures exert stronger pressures on unhealthy competition by high-profile publication than on time-consuming quality control by collaboration. Young investigators may lack a broad perspective on methodological standards and may be reluctant to deviate from a trotten path. MITOEAGLE, however, will bring a large group of mitochondrial experts together by demonstrating the added value for each individual project, when harmonization of protocols will allow scattered data to be combined as the only means to overcome severe limitations of the traditional scientific approach (Fortier et al 2010).
| |
|
| |
|
| ::: '''Sample size'''
| |
| :::: The complexity of evolutionary background, age, gender, lifestyle and environment (EAGLE) linked to mitochondrial function cannot be addressed in the conventional small-scale studies with 20 subjects (rather than 2,000 or 200,000). To come anywhere near to large sample sizes, pooling of information between studies is essential on a global scale.
| |
|
| |
|
| ::: '''Standardization''' | | == Acknowledgements: Contributions to COST Action MitoEAGLE == |
| :::: Rigorous standardization is the gold standard for data pooling, but may not be achievable at the present level of research in mt-physiology, where different preparation protocols, incubation media and respiratory protocols are used. Therefore, unrealistic efforts towards developing and implementing a defined standard will be replaced by a translation strategy: Major subprotocols (e.g. different respiration media) will be compared (facilitated by STSM and workshops) to allow quantitative conversion of results obtained by different groups following their specific ‘standard’ operating procedures. This will be a first evolutionary step towards harmonization and standardization. | | ::::* Use this sentence: This publication is based upon work from COST Action CA15203 MitoEAGLE, supported by COST (European Cooperation in Science and Technology) |
| | ::::* Use this logo: [https://www.mitoeagle.org/index.php/File:COST_EU_Logo.PNG COST logo] and [https://www.mitoeagle.org/index.php/File:MITOEAGLE-representation.jpg MitoEAGLE] |
| | :::::* More information to acknowledging the COST MitoEAGLE Action in your publications, abstracts, etc.: [https://www.cost.eu/visual-identity/ COST visual identity] |
| | :::::* The COST logos can be downloaded [http://www.cost.eu/media/dissemination-corporate-identity here] |
|
| |
|
| === Added value of networking ===
| |
| '''In relation to the challenge'''
| |
| :::: There is no QMS commonly available in the field of mitochondrial respirometry and bioenergetics. Without networking on a large scale it is not possible to implement a widely or even generally accepted set of standards that is required for harmonization of datasets. To implement the objectives of MITOEAGLE, it is necessary to bring together a large international group of experts. Teams from 32 countries will participate in this COST Action (25: AT, BE, CH, CZ, DE, EE, ES, ET, FR, HU, IE, IT, LT, LV, NL, NO, PL, PT, RO, RS, SE, SF, SK, UK, US) or have expressed an interest in collaboration (BR, CA, IN, NZ, ZA). Among the 24 European Member States in the MITOEAGLE network, 46% are Inclusiveness target countries. Researcher mobility will be supported through staff exchanges between labs, especially Early Career Investigators who will form the next generation of team leaders for European Research in mitochondrial physiology. This large Consortium will include opinion leaders and stakeholders, who will be crucial for disseminating the developed standards (protocols, ring tests) through their contacts and networks, in a preclinical phase before advancing these standards to the level of CE and FDA certification.
| |
|
| |
| '''In relation to existing efforts at European and/or international level'''
| |
| :::: The MITOEAGLE network will operate in close contact and complementary to various European and international mitochondrial organizations. International mitochondrial societies and European bioenergetics networks are, for example:
| |
| ::::* European Bioenergetics Conference (EBEC) organizes bi-annual conferences,
| |
| ::::* the Mitochondrial Physiology Society (MiP) has been founded in 2003 to organize conferences and summerschools worldwide,
| |
| ::::* the Mitochondrial European Education Training (MEET) is a project started in 2013, linking partners from 8 different countries.
| |
| ::::* International Mito Patients is a network of national patient organizations involved in mitochondrial disease;
| |
| ::::* DE: mitoNET - German Network for Mitochondrial Disorders;
| |
| ::::* FR: Association Contre Les Maladies Mitochondriales;
| |
| ::::* IT: COMETA - Coordinamento malattie metaboliche ereditarie;
| |
| ::::* RS: The Serbian Society for Mitochondrial and Free Radical Physiology (SSMFRP) was established in 2008 as a national Society;
| |
| ::::* UK: The Children's Mitochondrial Disease Network is the only UK charity dedicated to providing information and support for all mitochondrial disorders;
| |
| ::::* US: The United Mitochondrial Disease Foundation (UMDF) was founded in 1996 to promote research and education for the diagnosis, treatment and cure of mitochondrial disorders.
| |
|
| |
|
| | == Gallery == |
|
| |
|
| == Impact == | | <br/> |
| | <gallery mode=default perrow=4 widths="500px" heights="450px"> |
| | File:MiPschool 2018 group.jpg|[[MiPschool Tromso-Bergen 2018|MitoEAGLE/MiPschool 2018 Tromso to Bergen, NO]] |
| | File:Lund01.jpg|thumb|Upper left row: Shao-Chiang Chang, Ernesto Alfaro-Moreno, Luiz F Garcia-Souza, Erich Gnaiger, Johnny Stiban, Melanie Schartner, Eskil Elmér, Beata Cizmarova, Michael Karlsson, Anthony Molina, Johannes Ehinger, Fredrik Sjövall. Middle row: Slawomir Michalak, Basak Engin, Elisa Calabria, Carmina Silaidos, Zuzana Sumbalova, Vlad Avram, Imen Chamkha. Lower row: Cezary Watala, Joanna Rybacka-Mossakowska, Gloria Keppner, Eleonor Åsander Frostner, Chiara Volani, Magdalena Labienec-Watala, Karolina Siewiera, Sarah Piel |
| | File:MitoEAGLE-WG4 Pic5.JPG|[[MitoEAGLE Poznan 2018|WG4 Blood cell workshop and retreat - Poznan 2018]] |
| | File:Group picture.jpg|[[MiP2017/MitoEAGLE Hradec Kralove CZ|MiP2017/MitoEAGLE Hradec Kralove CZ]] |
| | File:20180130 152201.jpg|[[MitoEAGLE Innsbruck 2018-01-29|WG 4 blood cells workshop and retreat - Innsbruck 2018]] |
| | File:MITOEAGLE Training School 2017.jpg|[[MiPschool Obergurgl 2017|MitoEAGLE/MiPschool 2017 Obergurgl AT]] |
| | File:Mitoeagle Verona 2016.JPG|[[MitoEAGLE Verona 2016|MitoEAGLE - Verona 15-17 Nov 2016: A roadmap for MitoEAGLE and first steps]] |
| | File:DSC03729.jpg|[[MiP2018/MitoEAGLE Jurmala LV|MitoEAGLE Jurmala 18-21 Sep 2018: 13th Conference on Mitochondrial Physiology: The role of mitochondria in health, disease and drug discovery - COST MitoEAGLE perspectives and MitoEAGLE WG and MC Meeting]] |
| | File:TS2019.jpg|[[MiPschool Coimbra 2019|MitoEAGLE/MiPschool 2019 Coimbra, PT]] |
| | File:MiP2019 group picture.JPG|[[MiP2019/MitoEAGLE Belgrade RS|MiP/MitoEAGLE Conference and Meeting 2019 Belgrade, RS]] |
| | </gallery> |
|
| |
|
| === Expected impact ===
| |
| '''Short-term and long-term scientific, technological, and/or socioeconomic impacts'''
| |
| :::: The Action will build a capacity in the European Research Area and increase the reproducibility of studies in this field as well as the scientific knowledge. Networking between current and emerging groups will be initiated and sustained. This network will allow communication, exchange of ideas, and feedback between the groups involved. The research performed by the network members in the WGs will be financed independent of the COST action through local, national or international funding. MITOEAGLE will cover costs for the activities including management and meeting organization.
| |
| :::: In the short-term perspective this COST Action will result in
| |
| ::::# more effective national and trans-national research systems.
| |
| ::::# optimal transnational cooperation and joint grant applications among the involved groups.
| |
| ::::# an open recruitment of Early Career Investigators for STSMs and Workshops.
| |
| ::::# gender balance in the Action’s research training (STSMs and in Working Groups) and membership of the Management Committee.
| |
|
| |
|
| :::: In the long-term perspective the involved groups may penetrate the practice in basic science in this field. With development of the quality management system (QMS), the entire research field is pushed to a new level and thus impacts are expected on the entire field and its clinical application. The most important advantages will be:
| |
| ::::# Added value to existing data and publications.
| |
| ::::# More economical research by saving resources through standardized and harmonized protocols. Measurements will not be wasted due to lack of comparability.
| |
| ::::# Increased quality and validity of the research.
| |
| ::::# New possibilities of data sharing and data mining.
| |
|
| |
|
| === Measures to maximise impact ===
| |
| '''Plan for involving the most relevant stakeholders'''
| |
| :::: The MITOEAGLE consortium will emphasize the connections to established European and international mitochondrial networks, for exchange of expertise and harmonization of diagnostic approaches. Scientific societies and organizations will be approached to support the COST Action by integration of MITOEAGLE sessions into their regular conferences (Biochemical Society, FEBS, MiP Society, EUROMIT, EBEC). MITOEAGLE will encourage other research communities to join, by organizing open conferences and workshops as well as by informing about current and planned activities, and therefore increasing visibility, on the Action’s website.
| |
| :::: The MITOEAGLE consortium will emphasize the connections to established European and international mitochondrial networks, for exchange of expertise and harmonization of diagnostic approaches. Scientific societies and organizations will be approached to support the COST Action by integration of MITOEAGLE sessions into their regular conferences (Biochemical Society, FEBS, MiP Society, EUROMIT, EBEC). MITOEAGLE will encourage other research communities to join, by organizing open conferences and workshops as well as by informing about current and planned activities, and therefore increasing visibility, on the Action’s website.
| |
|
| |
| === Potential for innovation versus risk level ===
| |
| '''Potential for scientific, technological and/or socioeconomic innovation breakthroughs'''
| |
| :::: The Action is ambitious in setting up a QMS in order to create common prospective standards and a harmonization system for post-study analysis and feeding the MITOEAGLE database. The successful completion of this COST Action will lead to a deeper understanding of the biological interactions in the field of mitochondrial function, making research in this area more effective and fruitful. However, standardizing is difficult (e.g. tissue-specific protocols) and the comparability of results obtained with different instruments might suffer from varying quality control standards. An ‘absolute‘ gold standard may remain inherently unattainable, as is the case in most fields of contemporary bioscience. Practically, the least common denominator that can be agreed upon may remain disappointingly fragmented, particularly in a large and diverse consortium involving stakeholders represented by university-based and industry-based scientists. Senior stakeholders may be biased by a commitment to their established - scientifically published or commercially sold - procedural protocols, which appear to be ‘accepted’ (by peer review) or ‘accredited’ (by revenues).
| |
|
| |
| :::: Without generous project management, a large consortium may fail by default to agree on highly specific standards. In contrast, a minimally selected consortium is bound to reach consensus, however, without any chance of impacting on the larger scientific community. Even in the case of successful establishment of the QMS and hormonization protocols, the presently available amount of matching data for any specific mitochondrial variable may be small after filtering by the QMS. The MITOEAGLE COST Action may be merely a first small (but important) step, and is certainly a project that requires extension and persistence. MITOEAGLE may be seen as too ambitious in the short term, but indispensable at large.
| |
|
| |
|
| |
| [[File:MITOEAGLE Working groups.jpg|right|400px|MITOEAGLE Working Groups]]
| |
| == Implementation ==
| |
|
| |
| === Working groups ===
| |
| :::: Four Working Groups (WG) are planned to interact closely: WG1 elaborates the overall strategy, with input into Working Groups specializing on muscle tissue (WG2), fat tissue (WG3), blood cells and cultured cell lines (WG4). Feeding the data repositories, WG2-4 will implement the strategies, providing feedback to WG1, with feedforward in optimization cycles. These will lead to summaries of recommendations and a ‘Training and knowledge management concept’ (Fig. 2).
| |
|
| |
| ::: '''WG1. Standard operating procedures and user requirement document: Protocols, terminology, documentation'''
| |
| :::: ''More details'' » [[MITOEAGLE protocols, terminology, documentation]]
| |
|
| |
| ::: '''WG 2: MITOEAGLE data repository in muscle and other tissues'''
| |
| :::: ''More details'' » [[MITOEAGLE data: muscle]]
| |
|
| |
| ::: '''WG3. MITOEAGLE data repository on fat tissues and other tissues'''
| |
| :::: ''More details'' » [[MITOEAGLE data: fat]]
| |
|
| |
| ::: '''WG4. MITOEAGLE data repository for blood cells and clutured cells'''
| |
| :::: ''More details'' » [[MITOEAGLE data: blood and cultured cells]]
| |
|
| |
| ::: '''MITOEAGLE data repositories''' (from WG 2-4)
| |
| ::::# Deposit post-hoc datasets related to articles already published on topics of WG 2-4 by Consortium members on locations accessible for the Consortium.
| |
| ::::# Connect published articles to deposited datasets, using generally accessible tools such as PubMed Commons (http://www.ncbi.nlm.nih.gov/pubmedcommons/).
| |
| ::::# Along with development of SOPs, implement advance public deposition of protocols (Begley, Ioannidis 2015).
| |
| ::::# Deposit datasets with submitted manuscripts and finally connect these using tools such as PubMed Commons.
| |
|
| |
| === Risk and contingency plans ===
| |
| :::: Even in the very large consortium the availability of data, e.g. on mitochondrial respiratory function in human adipose tissue, may be limited and not yet suitable for a data repository. In this case, the consortium might decide for WG3 to (a) focus on model organisms, or (b) select a different tissue or tissues, or (c) be cancelled in favour of strengthening the other WGs. Depending on the expertise and specific interests of members in the Consortium, WG2 and WG3 may decide to include different tissues in their work plan. Later, fluctuations in the consortium may change such a focus. To secure a critical mass, additional funds may be required to achieve the goal of the Action, if additional tissues should be included (which is certainly a long-term aim beyond the Action).
| |
|
| |
| === Management structures and procedures ===
| |
| :::: This COST Action will be coordinated by a management structure with defined goals, timelines and specialist WGs. A Management Committee (MC) will coordinate the Action and inform partners at a regular interval, prepare progress reports and manage the budget. The Action Management Committee will design a plan to initiate the activities of the four Working Groups.
| |
| :::: The MC plays a key element regarding the coordination of this COST Action; it will direct and structure the Working Groups and define, organise and monitor the progress and the outcome of the collaborative interactions in the network continuously. The executive Board of the MC includes the coordinators of the 4 WGs. The responsibility of the Chairman will be a day-to-day management of this COST Action. He will form the network link to the Commission, will receive/disburse funds and maintain formal accounts through a Research Accountant.
| |
| :::: MC tasks will be:
| |
| ::::# Appointment of the Action Chair, Vice-chair and Action evaluation;
| |
| ::::# establishment and maintenance of a COST website: visibility of the Action itself, conferences, workshops, dissemination of working opportunities (PhD, Postdoc positions), interactions with other scientific societies, reports;
| |
| ::::# planning and organizing MC meetings, scientific meetings, workshops;
| |
| ::::# assessment of progress reports by the different WGs, monitoring the progress of their objectives;
| |
| ::::# reviewing and approving STSM and Workshop applications;
| |
| ::::# invitation of new participants to the COST Action;
| |
| ::::# enforcing cooperation between the WGs;
| |
| ::::# preparation of reports;
| |
| ::::# networking to other EU programmes and stakeholders;
| |
| ::::# ensuring no repetition within the COST participants and with other European programmes.
| |
| :::: MC meetings will take place at regular intervals, preferentially linked with scientific meetings. The structure of the MC meetings will be as follows: meetings in different places in Europe according to the preference of members of the COST Action. Restricted MC meetings (Chair, Vice-chairs, WG coordinators) through tele- or video-conferences will be organized between the regular MC meetings to ensure efficient coordination of the activities. Meetings will be minuted to ensure transparency. To monitor the achievements of objectives and milestones, annual reports of the WGs will be prepared and submitted to the MC. These reports will be evaluated and discussed at MC meetings and appropriate decisions will be made.
| |
|
| |
| === Network as a whole ===
| |
| :::: The enormous interest in this COST MITOEAGLE Action underlines the necessity and ‘am Impuls der Zeit sein’ of such a project. At this stage the Action has already secured the interest of research centres in 24 different European countries, furthermore, numerous International Partner Countries (IPCs) have indicated their interest in the Action. IPCs and Near Neighbour Countries (NNCs) are needed for the success of this Action, which tries to solve a problem of global importance. All the involved countries will benefit from this Action by increasing the scientific and financial efficacy of their research through implementing international MITOEAGLE standards. The broad geographical distribution of participating countries allows an optimum exchange of information and lays a foundation for a long-term international cooperation, going beyond the timeframe of the COST Action itself.
| |
| :::: The COST MITOEAGLE Network comprises a high number of experienced researchers as well as ECIs, giving the latter the possibility to learn from international experts and subsequently giving them the chance to start building up their own research groups. The participating countries will profit from the active exchange that will strengthen their local research and consolidate its future.
| |
| :::: To optimize the participation possibilities for researchers of all the involved countries, network meetings and activities will be spread across Europe. A special focus will be laid on including Inclusiveness Target Countries (46% of the countries in this Action). Interaction with other COST Actions and European as well as international programmes will be stimulated throughout the duration of the Action.
| |
|
| |
|
| |
|
| |
| == Satellite meetings ==
| |
| Organize a series of meetings of members of the consortium with a minimum of added costs, by integrating EAGLE sessions in regular meetings of established [[MitoGlobal_Organizations |mitochondrial societies]]. Keep a track record for information flow to attending participants.
| |
|
| |
|
| |
| === Workshops ===
| |
| Satellite workshops will extend the activities of the consortium, which may lead to continuing inter-laboratory studies, development of standards for quality control and teaching initiatives to disseminate and certify such standards for quality control.
| |
|
| |
|
| |
| === Intergration with established and developing databases ===
| |
| Contact organizations and research groups operating comparable genomic and physiological databases, to share their expertise. Interdisciplinary expertise is required on the design of the MITOEAGLE data base, considering the complexities of the logistic, legal and financial aspects.
| |
|
| |
|
| |
| == Links ==
| |
| * [http://www.cost.eu/COST_Actions/ca/CA15110? CA COST Action CA15110] - '''Harmonising standardisation strategies to increase efficiency and competitiveness of European life-science research'''
| |
| :: OBJECTIVE: The main objective is to avoid duplication and overlap of existing standardisation activities and to achieve a breakthrough in standardisation efforts; the Action aims to bridge, combine and team up with other initiatives. This shall be achieved through a coordinated, long-term strategy by active involvement of all stakeholders from research, industry and policy.
| |
|
| |
| * National Exercise Clinical Trials Network (contact [[Lai Nicola]])
| |
| :: http://www.uab.edu/medicine/exercise/nextnet
| |
| :: To share exercise data among the different national labs we are using redcap: http://www.project-redcap.org/
| |
|
| |
| * NINDS Mitochondrial Diseases Common Data Element Project - Public Review Period: November 20, 2014 - January 16, 2015
| |
| :: http://www.commondataelements.ninds.nih.gov/MITO.aspx#tab=Data_Standards
| |
|
| |
| * Work in progress: [[MiPMap]]
| |
| [[File:Logo MitoFit.jpg|200px|link=MitoFit-O2k|MitoFit]] '''[[MitoFit-O2k|MitoFit]]'''
| |
|
| |
|
| | {{MITOEAGLE banner}} |
|
| |
|
| [[Category:Mitochondrial Global Network]] | | [[Category:Mitochondrial Global Network]] |
